Fellow Health, a provider of mail-in semen analysis services, has announced it has delivered over 100,000 patient test results since its product launch in 2020. The company reports its testing volume has increased by more than 50% year-to-date from 2023.
The company’s mail-in semen analysis service aims to improve access to male fertility testing, addressing a market where 1 in 6 couples experience fertility issues worldwide. Fellow Health’s offering is currently the only mail-in fertility test with peer-reviewed validation data demonstrating its analysis accuracy.
“We have always put scientific rigor first, designing a preservative solution that maintains sample integrity and ensures results are as accurate as if the sample was tested within one hour of being produced,” explained Brian Hogan, CEO of Fellow Health. The company’s research has resulted in over 30 peer-reviewed publications and presentations at scientific meetings.
In addition to fertility testing, Fellow Health provides post-vasectomy testing services. This offering targets the approximately 500,000 men who undergo vasectomies annually in the U.S., particularly addressing needs of those with limited access to in-person clinics.
The company reports it currently serves more than 1,500 clinical practices, including 11 of the top 15 U.S. hospitals. “Fellow Health’s growth reflects our team’s progress in transforming patient health,” said Will Matthews, founder of Fellow Health. “We are eager to continue pushing the boundaries of what’s possible in male reproductive health.”
Founded in 2018, Fellow Health has secured funding from life sciences and technology investors including 5AM Ventures, Genoa Ventures, Human Capital, and Mantis Venture Capital. The company processes over 300 patient samples daily through their CLIA-certified lab.
